The genetics of dementia by Farlow, Janice L. & Foroud, Tatiana
The Genetics of Dementia
Janice L. Farlow, BS, BA1 and Tatiana Foroud, PhD1
1Department of Medical and Molecular Genetics, Indiana University School of Medicine,
Indianapolis, Indiana
Abstract
Over the past decade, there has been a dramatic evolution of genetic methodologies that can be
used to identify genes contributing to disease. Initially, the focus was primarily on classical
linkage analysis; more recently, genomewide association studies, and high-throughput whole
genome and whole exome sequencing have provided efficient approaches to detect common and
rare variation contributing to disease risk. Application of these methodologies to dementias has led
to the nomination of dozens of causative and susceptibility genes, solidifying the recognition that
genetic factors are important contributors to the disease processes. In this review, the authors
focus on current knowledge of the genetics of Alzheimer's disease and frontotemporal lobar
degeneration. A working understanding of the genes relevant to common dementias will become
increasingly critical, as options for genetic testing and eventually gene-specific therapeutics are
developed.
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Overview of Modern Genetic Technologies
The past few decades have seen exponential advances in the ability to identify genes
contributing to disease. Beginning with the identification of microsatellite markers and then
single nucleotide polymorphisms (SNPs) in the early 1990s, researchers were able to
interrogate the genome to detect genes causing Mendelian disorders. Linkage analysis was
the most common use of these markers and sought to identify chromosomal regions shared
by affected members within a family. It was hypothesized that a gene that caused the disease
lay within these shared chromosomal regions. The result of linkage analysis was a rapid
identification of the genetic cause for many Mendelian disorders. This in turn has provided
key insights into disease pathogenesis and in some cases has led to novel therapeutics.
Over the past decade, advancing genetic technologies have allowed millions of SNPs to be
efficiently interrogated using genotyping arrays. These arrays include primarily common
variation and have allowed scientists to explore new hypotheses about the role of genetics in
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human disease. For example, studies can now be designed to identify genetic factors that
increase or decrease the risk of disease. The most common approach that has been used is a
genomewide association study (GWAS), which compares a sample of cases with disease to
controls who do not have the disease. Because many genetic risk factors have modest
individual effect on disease risk, large samples of cases and controls are needed to obtain
robust, reproducible associations. More recently, meta-analysis has been widely used to
combine results from multiple studies. This has resulted in studies using data from
thousands of cases and controls to identify SNPs that are associated with disease risk. A
GWAS is based on the premise of linkage disequilibrium, meaning that many SNPs are
tested and used as proxies for the entire genome. Thus, analyses can determine that a SNP is
associated with disease risk, but cannot confirm that this particular SNP functionally
contributes to disease risk.
In the past few years, technology has further advanced to allow sequencing of DNA to be
cost effective on a large scale. Rather than limiting sequencing to a gene or a small region of
a chromosome, it is now possible to sequence the entire genome (whole genome
sequencing) or only the gene-coding regions, the gene exons (whole exome sequencing).
The ability to perform such extensive DNA sequencing has allowed researchers to examine
the role of rare variation in disease. For example, whole exome sequencing within a family
or across many families can be used to identify genes in which rare variants are found at
greater frequency among the affected individuals as compared with control subjects who do
not have the disease. Whole exome sequencing is often focused on the identification of rare,
functional variants, which may alter the structure or function of the resulting protein. The
types of variants that can be identified with this method are not limited to single nucleotide
variants, but can also include small insertions and deletions.
Whole exome and whole genome sequencing presents a challenge to researchers due to the
large number of sequence variants that are identified (~ 40,000 per exome and 3 million per
genome). Large numbers of subjects are required to identify candidate genes in complex
diseases like Alzheimer's disease (AD), and the cost is often prohibitive. New
bioinformation technologies are constantly in development for analysis of sequencing
experiments, but further effort will be required to validate, compare, and combine these
tools. Almost all of these genetic tools and technologies have been used to study dementia.
This review will describe what has been learned about the genetics of specific types of
dementia, Alzheimer's disease, and frontotemporal lobar degeneration (FTLD).
The Genetics of Alzheimer's Disease
Alzheimer's disease is the most common neurodegenerative disorder among the elderly, as
well as the most common cause of dementia overall. The key neuropathologic findings in
AD are amyloid plaques composed of β-amyloid (Aβ) and neurofibrillary tangles consisting
of the tau protein. Alzheimer's disease is likely caused by a combination of genetic and
environmental factors. Alzheimer's disease is typically categorized into early onset (EOAD;
onset < 60 years) and late-onset (onset ≥ 60 years). Early-onset Alzheimer's disease makes
up less than 5% of cases, but because a subset of families has a clear pattern of Mendelian
inheritance, mutations have been identified in several causative genes. The identification of
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these genes has significantly advanced the understanding of the biological underpinnings of
all AD cases.
Early-Onset Alzheimer's Disease
Researchers observed that among families with EOAD, a significant number displayed
autosomal dominant inheritance. This allowed linkage analysis to be successfully employed
to identify three causative genes (APP, PSEN1, and PSEN2).
APP was the first EOAD gene to be identified.1,2 It is located on chromosome 21 and
encodes the β-amyloid precursor protein. The β-amyloid precursor protein is a neuronal
protein that is sequentially cleaved by two specific proteases (β-secretase and γ-secretase) to
release Aβ. Even before APP was identified, biochemical analysis had identified cerebral
Aβ deposits in the brains of patients with AD. In addition, it had been found that patients
with Down's syndrome were more likely to develop AD; therefore, it was predicted that a
gene on chromosome 21 would function to produce Aβ and would cause AD when
mutated.3
Mutations in APP are found in less than a quarter of EOAD patients. A variety of different
mutations have been found in APP including point mutations, gene duplications, and gene
deletions. All APP mutations reported to be pathogenic are located at secretase sites or
inside the sequence for the resulting Aβ peptide, in or near exons 16 and 17 (Fig. 1).4
The majority of EOAD mutations are found in the presenilin 1 (PSEN1) gene, located on
chromosome 14 and discovered a few years after APP.5 There have been 185 different
mutations found in this gene alone, most clustering in the transmembrane portion of the
protein. Sequence homology with PSEN1 prompted the relatively rapid identification of the
presenilin 2 (PSEN2) gene on chromosome 1.6,7 Mutations in this gene are quite rare and
were initially due to a founder mutation among individuals of Volga-German ancestry.
Mutations in PSEN2 have now been found in individuals of other ancestry as well.8–10 Of
those that have been reported as pathogenic mutations, the distribution within resultant
protein domains is similar to that of PSEN1. Together, presenilin 1 (PSEN1) and presenilin 2
(PSEN2) serve as critical catalytic components of the γ-secretase.11
Over 200 different mutations have been identified in these three EOAD genes, and most are
fully penetrant (Table 1; consult the Alzheimer Disease and Frontotemporal Dementia
Mutation database, http://www.molegen.ua.ac.be/ADMutations, for updated information).12
Disease-causing mutations in these three genes all lead to an increase in extracellular Aβ or
a relative overabundance of the Aβ42 species, which is thought to increase Aβ aggregation
and amyloid fibril formation.13 The discovery of APP, PSEN1, and PSEN2 contributed to
the amyloid hypothesis, which posits that amyloid plays a critical role in AD pathology.
Late-Onset Alzheimer Disease
Although most LOAD cases do not have a clear heritable etiology, genetic factors still play
an important role in disease risk. The lifetime risk of developing AD is ~ 10%, and is twice
that for individuals having an affected first-degree relative with AD.14 Studies have
estimated that the genetic contribution to LOAD susceptibility (i.e., heritability) is as high as
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80%.15 Of note, no single gene has been identified that has a causative effect on disease risk
in LOAD, which would be analogous to the role of APP, PSEN1, or PSEN2 in EOAD.
The apolipoprotein E gene (APOE) was the first gene discovered as a risk factor for LOAD,
and it remains the identified locus that confers the greatest susceptibility to the disease.
APOE is a well-known gene involved in lipid metabolism, and it is thought to be important
in Aβ clearance, as well. There are three isoforms of APOE (ε2, ε3, ε4) that differ by a
single amino acid substitution. It has been shown that this minor difference leads to different
levels of clearance of Aβ, with the ε4 allele of APOE (APOE4) significantly decreasing the
speed of clearance at the blood–brain barrier.16
The ε4 allele of APOE (APOE4) increases the risk of AD with reported odds ratios ranging
from 4 to 15.17 The effect of APOE4 is consistently present across populations and
ethnicities.18–20 The APOE4 effect is additive, with those having two APOE4 alleles having
a 15-fold greater risk of AD as compared with the 4-times increased risk for those carrying a
single copy of the risk allele.21 Meanwhile, the ε2 allele (APOE2) decreases the risk of AD
by approximately a quarter, and is considered a protective allele.21 The ε3 allele of APOE
(APOE3), the most common of the 3 APOE isoforms, has not been shown to have a
detrimental or protective effect. Importantly, the APOE2 and APOE4 alleles modify the risk
of AD, but neither is causative (i.e., sufficient to cause or protect against AD alone).
Other than APOE, almost 50 additional genetic risk factors have now been linked to AD.
Varying levels of support exist for each gene. Nine genes have been labeled as established
risk factors for AD, based on genome-wide significance (p value ≤ 5 × 10–8) in meta-
analyses and replication in multiple studies.22 Much work remains to characterize exact
variants in or near these susceptibility genes; however, the genes have been linked to the
metabolism of Aβ and synaptic function (APOE, BIN1, CD33, CLU, CR1, PICALM), the
immune system and inflammation (ABCA7, CD33, CLU, CR1, MS4A), and lipid metabolism
(ABCA7, APOE, BIN1, CLU, PICALM). These susceptibility genes, with the exception of
APOE, all confer a relatively small risk for AD, with odds ratios of 0.85 to 1.2 (Table
2).23,24 The proportion of LOAD cases that could be prevented if these nine (GWAS-
identified) genetic risk factors were eliminated, referred to as the cumulative population
attributable risk, is estimated to be as high as 35%.25 Studies are actively underway to
identify additional disease-related associations in LOAD.
Genetics of Frontotemporal Lobar Degeneration
Frontotemporal lobar degeneration (FTLD) is a term that describes the neuropathology
underlying several different clinical syndromes, all characterized by progressive damage to
the frontal and/or temporal lobes of the brain. As a result, behavior and language are
progressively impaired in individuals affected with FTLD. Frontotemporal lobar
degeneration typically presents at an earlier age than AD (~ 45–65 years of age) and
represents the second most common cause of dementia in those under 65 years of age.
Almost half of individuals with FTLD have other affected family members, and an
autosomal dominant mode of transmission can be identified in ~ 10% of patients.26
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Six unrelated genes with over 150 reported mutations have been implicated in FTLD (Table
3; Alzheimer Disease and Frontotemporal Dementia Mutation database). Mutations in three
genes (C9ORF72, GRN, MAPT) are the most common, with rarer causative mutations found
in the remaining three genes (CHMP2B, TARDBP, VCP). Individuals with mutations in
C9ORF72, GRN, or MAPT often present with the most common frontotemporal dementia
clinical syndrome, the behavioral variant (bvFTD). Together, mutations in these three genes
account for at least 17% of familial FTLD.27 Although there are strong correlations between
the mutated gene and the patient's neuropathology, there is typically not a clear association
between the implicated gene and clinical phenotype.27
Microtubule-associated protein tau (MAPT), located on chromosome 17, is involved in
microtubule assembly and maintenance, and has been implicated in FTLD, AD, and other
neurologic diseases.28–30 Over 40 mutations have been reported in the gene since its
discovery in 1998, mostly in exons 9–13 (Fig. 2). Mutations result in a change in the ratio of
the three amino acid (3R) and four amino acid (4R) isoforms and are believed to increase the
tendency of tau to form neurotoxic aggregates. Mutations in MAPT are found in ~ 9 to 21%
of FTD patients.31
Some FTLD families demonstrated genetic linkage to chromosome 17, but surprisingly no
mutations in MAPT could be found. It was later discovered that many of these families had
mutations in progranulin (GRN), located only 6 Mb from MAPT.32,33 Over 60 disease-
producing mutations have been reported in GRN. Most result in a premature stop codon and
the resulting mRNA is degraded through nonsense-mediated decay resulting in haplo
insufficiency.34 Of note, there is substantial clinical variability in patients carrying a GRN
mutation. Mutations have been reported among individuals diagnosed clinically with
language variants and bvFTD, AD, corticobasal degeneration, and mild cognitive
impairment. The age of onset has varied widely, even within families.35 GRN mutations are
found in ~ 4 to 23% of all FTLD patients.31
Recently, expansions of a GGGGCC hexanucleotide repeat in the noncoding portion (first
intron) of C9orf72 on chromo-some 9 have been associated with both FTLD and
amyotrophic lateral sclerosis (ALS).36–39 The repeat number, typically less than 25 units in
normal individuals, is expanded to greater than 60 units in FTLD. The expanded number of
repeats results in the loss of one alternatively spliced transcript. However, the function of
this lost transcript is not yet known. Estimations for the percentage of familial ALS and
familial FTLD cases in North American populations attributable to the C9orf72 mutation
range from 23.5 to 36.2% and 6.3 to 19.1%, respectively.39 The C9orf72 mutation appears
to be more common among northern European populations.35
Mutations in the other three genes, chromatin modifying 2B (CHMP2B), valosin-containing
protein 1 (VCP-1) and TARDNA-binding protein 43 encoding gene (TARBDP), are rare
causes of FTD, found in only a few families each. The pheno-type in each is quite different
and may also be associated with non-FTD phenotypes. For example, some VCP-1 mutations
are associated with Paget's disease of the bone.35
Farlow and Foroud Page 5
Semin Neurol. Author manuscript; available in PMC 2014 November 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
There has only been one systematic FTLD GWAS, which reported TMEM106B on
chromosome 7 as a potential susceptibility gene for FTLD cases with TAR-DNA-binding
protein inclusions.40 The identified SNPs were associated with increased TMEM106B
expression, but the mechanism of upregulation and the development of FTLD has not been
established.
Genetic Counseling and Testing
Definitive diagnoses for AD and FTD can only be made at autopsy, but genetics may be
used to increase diagnostic and prognostic accuracy. With the current limitations regarding
disease-modifying therapies for neurodegenerative diseases and the complex ethical
considerations involved in genetic testing, clinicians must carefully consider the
appropriateness of genetic analyses for patients. Because both positive and negative findings
have significant implications for the patient and family, thorough genetic counseling is
advised before and after any genetic testing is performed. For genetic tests that are not
commercially available, the tests may be available in the academic research setting. As more
is learned about the genetics of AD and FTLD, commercial availability of genetic testing,
and even direct to consumer testing, will likely increase. As treatments are developed,
testing options will likely expand further. Clinicians will need to be familiar with these
options in an effort to counsel patients.
At present, routine DNA testing in AD is advisable only for EOAD, if the presenting
affected individual is a young or middle-aged adult (onset < 60 years). Testing for mutations
in PSEN 1, PSEN 2, and APP is currently commercially available. APOE genotyping is also
available, and there are ongoing studies assessing the advantages and disadvantages of
APOE genotyping. Most groups do not currently recommend the test for predictive risk
assessment.41
With the heterogeneity of FTLD, the recommendations for genetic testing in symptomatic
patients and their families are more complex. Considerations include the type of FTLD, the
extent of family history, and the availability and findings of autopsy tissue from an affected
family member. Genetic testing is available for MAPT, GRN, VCP, and C9orf72 in the
United States. A full algorithm for when genetic testing should be recommended has been
previously reported.42
Conclusion and Outlook
Although much has been discovered about the genetics of dementia, the genetic contribution
to the vast majority of sporadic and some Mendelian cases of dementia has not yet been
elucidated. Modern genetic technologies have helped identify causative and risk loci, but
much work remains to characterize the biological mechanisms of these genes and the
disease-producing mutations. As additional genetic loci are recognized and characterized,
correlations between genotypes and phenotypes will become better understood. Phenotypes
will not only include presenting symptoms, but also biomarkers such as structural and
functional imaging and composition of the cerebrospinal fluid. Methodologies for screening,
diagnosis, and prognosis will improve as additional genes and mutations are identified and
correlated with increasingly specific phenotypes. Most importantly, advancing knowledge of
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underlying genetic factors in neurodegenerative dementias will inform the pursuit of
preventative and disease-modifying therapies.
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Fig. 1.
Location of mutations within the APP protein product as generated from the Alzheimer
Disease and Frontotemporal Dementia Mutation database.12 Depicted is the chain of amino
acids produced from the APP gene. Green indicates sites of reported nonpathogenic
mutations, and red indicates sites of reported pathogenic mutations. Sites of cleavage by
secretases are shown in blue.
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Fig. 2.
Location of mutations within the MAPT protein product as generated from the Alzheimer
Disease and Frontotemporal Dementia Mutation database.12 Depicted is the chain of amino
acids produced from the MAPT gene. Green indicates sites of reported nonpathogenic
mutations, and red indicates sites of reported pathogenic mutations. Exon boundaries are
marked by Ex*, and microtubule-binding domains are shown in blue.
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Table 1
Mendelian genes causing familial early-onset Alzheimer's disease (EOAD)
Gene Protein Chromosome location Mutation frequency in EOAD
patientsa
Types of mutations reported
APP B-amyloid precursor protein 21q21.2 6–26% Missense, duplications, deletions
PSEN1 Presenilin 1 14q24.3 28–61% Missense, deletions, insertions
PSEN2 Presenilin 2 1q31–42 Rare Missense
a
Mutation frequencies reported by Cohn-Hokke et al.31
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Table 2
Established risk loci for late-onset Alzheimer'sdisease
Gene Protein Chromosome location Effect size / Odds ratio (95% CI)a
ABCA7 ATP-binding cassette, subfamily A, member 7 19p13.3 1.23 (1.18–1.28)
APOE Apolipoprotein E 19q13.32 ε3ε4 genotype 3.2 (2.8–3.8)
ε4ε4 genotype 14.9 (10.8–20.6)
BIN1 Bridging integrator 1 2q14.3 1.17 (1.13–1.20)
CD2AP CD2-associated protein 6p12.3 1.12 (1.08–1.16)
CD33 CD33 molecule 19q13.41 0.85 (0.86–0.92)
CLU Clusterin 8p21.1 0.89 (0.86–0.91)
CR1 Complement component receptor 1 1q32.2 1.19 (1.09–1.30)
MS4A4E, MS4A6A Membrane-spanning 4-domains, subfamily A,
member 4E and 6A
11q12.2 0.90 (0.88–0.93)
PICALM Phosphatidylinositol binding clathrin assembly
protein
11q14.2 0.88 (0.86–0.91)
a
Effect sizes calculated from AlzGene meta-analysis.22
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Table 3
Mendelian genes causing frontotemporal lobar degeneration (FTLD)
Gene Protein Location Mutation frequency in FTLD
patientsa
Types of mutations reported
MAPT Microtubule-associated protein tau 17q21.1 9–21% Missense, deletions
CRN Progranulin 17q21.31 4–23% Missense, deletions, insertions
C9orf72 Chromosome 9 open reading frame 72 9p21 18–30% Hexanucleotide repeat expansion
TARDBP TAR DNA binding protein 1p36.22 Rare Missense
VCP Valosin-containing protein 9p13.3 Rare Missense
CHMP2B Charged multivesicular body protein 2B 3p11.2 Rare Missense
a
Mutation frequencies calculated by Cohn-Hokke PE et al.31
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